Development of markers for the early detection and monitoring of prostate cancer.
ProteoMediX AG is a privately held diagnostic company that was founded in March 2010 as a spin-off company from ETH Zurich. ProteoMediX enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first products are focusing on prostate cancer, the most frequently diagnosed cancer in men, where neither the detection nor the effective treatment is currently guaranteed. ProteoMediX owns the exclusive commercial rights on a set of protein-based biomarkers that were discovered with state-of-the-art proteomics technology developed at the ETH Zurich. These biomarkers are directly linked to the origin of cancer on a molecular level and allow to capture the complexitiy of the disease by combining multiple biomarkers. A combination of these showed superior results for the accurate detection of prostate cancer when compared to the current standard PSA test in a clinical proof of concept study.
|26.04.2013||ProteoMediX Announces Publication of Results of its Biomarkers|
|27.09.2012||Winner of the Swiss Technology Award 2012|
|27.09.2012||Swiss Life Sciences Prize 2012|
|21.06.2012||Winner of the W. A. de Vigier Award|
|12.01.2012||ProteoMediX Raises CHF 2.6 million in Series A Financing|
|Videos, Slides & more|
ProteoMediX: Finalist zkb pionierpreis technopark 2013